Cancer immunotherapy Clinical Trials: Concepts and ChallengesApril 4-5, 2013National Institutes of Health CampusBethesda, MDProgram OrganizersThomas A. Davis, MD - Celidex therapeutics, IncorporatedSamir N. Khleif, Md - Georgia Regents UniversityHoward Streicher, MD - National Institutes of HealthDavid F. Stroncek, MD - National Institutes of Health Program SummaryThis two-day workshop will outline the current challenges posed by the development of therapeutic trials in immunotherapy. Several of these trials will be examined in greater detail, including preclinical testing requirements for clinical development, innovative clinical trial design, appropriate patient selection, end point determination, and developing combination therapies to improve long term disease management and survival. Accelerating anticancer agent development, validation and approvals will also be discussed. It is expected that, at the conclusion of the workshop, participants and speakers will have developed a framework or recommendations on how to design better clinical trials. Target AudienceThe target audience for this program includes academic researchers, industry and biotech company representatives, preclinical pharmaceutical developers, oncologists, investors/venture capitalists, biopharmaceutical consultants, and health care professionals engaged in clinical trials of cancer immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com